Three years of growth hormone therapy in children born small for gestational age: Results from the answer program

Robert Rapaport, Peter A. Lee, Judith L. Ross, Paul Saenger, Vlady Ostrow, Giuseppe Piccoli

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Growth hormone (GH) is used to treat short stature and growth failure associated with growth disorders. Birth size and GH status variably modulate response to GH therapy. The aim of this study was to determine the effect of birth size on response to GH therapy, and to determine the impact of GH status in patients born small for gestational age (SGA) on response to GH therapy. Data from the prospective, non-interventional American Norditropin Studies: Web-Enabled Research (ANSWER) Program was analyzed for several growth outcomes in response to GH therapy over 3 years. GH-naïve children from the ANSWER Program were included in this analysis: SGA with peak GH ≥10 ng/mL (20 mIU/L), SGA with peak GH <10 ng/mL (20 mIU/L), isolated growth hormone deficiency (IGHD) born SGA, IGHD not born SGA and idiopathic short stature. For patients with IGHD, those who did not meet criteria for SGA at birth showed greater improvements in height SDS and BMI SDS than patients with IGHD who met criteria for SGA at birth. For patients born SGA, response to GH therapy varied with GH status. Therefore, unlike previous guidelines, we recommend that GH status be established in patients born SGA to optimize GH therapy.

Original languageEnglish (US)
Pages (from-to)1096-1104
Number of pages9
JournalEndocrine Connections
Volume7
Issue number10
DOIs
StatePublished - 2018

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Three years of growth hormone therapy in children born small for gestational age: Results from the answer program'. Together they form a unique fingerprint.

Cite this